Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome
GlobeNewswire - Thu Apr 10, 11:30AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that it has submitted a protocol to the FDA for a Phase IIb clinical trial for its MDX product candidate for the treatment of patients with Fragile X Syndrome.
Alcobra Announces Shares Uplisted to NASDAQ Global Market
GlobeNewswire - Wed Mar 26, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that its stock has been approved to list on the Nasdaq Global Market, effective with the open of the stock market on Friday, March 28, 2014. Until the stock is transferred to Nasdaq Global Market, ADHD's stock will continue to trade on the Nasdaq Capital Market. The company will continue to trade under its existing ticker symbol "ADHD."
Pipeline Update from Alcobra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 11:10AM CDT
Alcobra enrolled the first patient in a randomized, placebo-controlled phase III study on metadoxine extended release (MDX) for attention deficit hyperactivity disorder (ADHD).
Today’s Top Biotech Stories: Prosensa, Medivation, and Alcobra
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 18, 8:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at this three top stocks -- Prosensa , ...
Alcobra Announces Enrollment of First Patient in Phase 3 Clinical Trial for MDX in Adult ADHD
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that, following the recent FDA acceptance of the Company's IND for MDX, the first patient has been enrolled in a Phase 3 clinical trial of MDX in the treatment of Adults with ADHD.
Alcobra Gains IND Clearance for MDX - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:40PM CST
Alcobra's IND application for Metadoxine Extended Release (MDX) has been cleared by the U.S. FDA recently.
Alcobra Announces FDA Clearance of IND for Metadoxine Extended Release (MDX)
GlobeNewswire - Fri Mar 07, 2:57AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX) to treat cognitive dysfunctions, such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced today that the US. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for MDX. This step will allow for the initiation of US clinical trials.
Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:04AM CST
Alcobra Ltd. was a big mover last session, as the company saw its shares rise by over 8% on the day.
Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference
GlobeNewswire - Mon Feb 24, 7:08AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine extended-release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that Dr. Jonathan Rubin, Chief Medical Officer of Alcobra, will give a presentation entitled, "The Use of Biomarkers in Fragile X and Autism Clinical Trials," at Autism Speaks' Autism Investment Conference, being held at the Bently Reserve Banking Hall in San Francisco on March 4-5, 2014. The Alcobra presentation is on Tuesday, March 4, during the "Medicines and Therapeutic Devices" session.
Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer
GlobeNewswire - Wed Feb 19, 7:00AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, Metadoxine Extended Release (MDX; MG01CI), to treat cognitive dysfunction, announced today that it has appointed Dr. Tomer Berkovitz as Chief Financial Officer, effective May 1, 2014. Dr. Berkovitz will report to Dr. Yaron Daniely, President and Chief Executive Officer, and will be responsible for all Corporate Finance and Accounting activities for Alcobra.
Alcobra Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Corporate Update
GlobeNewswire - Thu Feb 13, 7:00AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced its financial results for the quarter and year-ended December 31, 2013.
Alcobra Ltd submits IND to US FDA for Phase III development programme of MG01CI in adults with ADHD
M2 - Mon Feb 10, 6:55AM CST
Biopharmaceutical company Alcobra Ltd (NasdaqCM:ADHD) said on Friday that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) to initiate a Phase III clinical trial with MG01CI.
Alcobra Announces IND Submission for Extended Release Metadoxine to Treat Adults With ADHD
GlobeNewswire - Fri Feb 07, 12:59PM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced the submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial with MG01CI. The study is entitled "A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD)."
Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)
Alcobra Ltd. to Provide Corporate Overview at 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Fri Jan 31, 7:00AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at the BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City on February 10-11, 2014. The Alcobra presentation is on Monday, February 10 at 3:30pm Eastern Time.
Alcobra Ltd. to Release Fourth Quarter 2013 Results and Host Investor Conference Call on Thursday, February 13, 2014
GlobeNewswire - Wed Jan 29, 7:00AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter of 2013 and will host a corporate update conference call on Thursday, February 13, 2014.
Alcobra Announces New Biomarker Finding in a Follow-Up Fragile X Animal Study for MG01CI
GlobeNewswire - Mon Jan 27, 7:00AM CST
- Improved Cognitive Function and Social Interaction Correlated With Changes in Blood Levels of Fragile X-Specific Molecular Targets
Fragile X Syndrome - Pipeline Review, H2 2013
M2 - Thu Jan 23, 8:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/gmtj7c/fragile_x) has announced the addition of the "Fragile X Syndrome - Pipeline Review, H2 2013" report to their offering. 'Fragile X Syndrome - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fragile X Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fragile X Syndrome. Scope - A snapshot of the global therapeutic scenario for Fragile X Syndrome. - A review of the Fragile X Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fragile X Syndrome pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Fragile X Syndrome. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Fragile X Syndrome pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Companies Mentioned F. Hoffmann-La Roche Ltd. Novartis AG Paratek Pharmaceuticals, Inc. Neuren Pharmaceuticals Limited Cortex Pharmaceuticals, Inc. Seaside Therapeutics, LLC Snowdon Inc. Marinus Pharmaceuticals, Inc. Nexgenix Pharmaceuticals, LLC aFraxis Inc. Alcobra Ltd Sage Therapeutics Confluence Pharmaceuticals LLC SMaRT Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/gmtj7c/fragile_x About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Six Israeli Biotech New Issues Set A Blistering Pace
at Investor's Business Daily - Tue Jan 14, 5:12PM CST
Biotech stocks have been gaining in strides lately, with the 279-stock industry group up 15% so far in January and ahead 85% over the past 52 weeks. Most of those are U.S.-based. But 11 stocks in the group are Israeli. That is more biotechs than...